• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DACARBAZINE Drug Record

  • Summary
  • Interactions
  • Claims
  • DACARBAZINE chembl:CHEMBL476 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    DTIC
    DIC
    NSC-45388
    NCI C04717
    DACARBAZINE
    DTIC-DOME
    5-(DIMETHYLTRIAZENO)IMIDAZOLE-4-CARBOXAMIDE
    NCI-C04717
    4-(DIMETHYLTRIAZENO)IMIDAZOLE-5-CARBOXAMIDE
    BIOCARBAZINE
    DACARBAZINUM
    IMIDAZOLE CARBOXAMIDE
    IMIDAZOLE-4-CARBOXAMIDE, 5-(3,3-DIMETHYL-1-TRIAZENO)-
    (E)-DACARBAZINE
    4-(5)-(3,3-DIMETHYL-1-TRIAZENO)IMIDAZOLE-5(4)-CARBOXAMIDE
    4-(3,3-DIMETHYL-1-TRIAZENO)IMIDAZOLE-5-CARBOXAMIDE
    DACARBAZINA
    5-(3,3-DIMETHYLTRIAZENO)IMIDAZOLE-4-CARBOXAMIDE
    DTIE
    ICDMT
    DTIC-DOME (TN)
    NSC 45388
    HSDB 3219
    DTIC-DOME®
    DTCI
    5-(3,3-DIMETHYL-1-TRIAZENO)IMIDAZOLE-4-CARBOXAMIDE
    DACARBAZIN
    chemidplus:4342-03-4
    chembl:CHEMBL476
    drugbank:00851
    rxcui:3098

    Drug Info:

    Drug Class antineoplastic agents
    Year of Approval 1975
    FDA Approval 1975
    Drug Class small molecule
    Drug Indications Antineoplastic Agents
    (4 More Sources)

    Publications:

    Lewis BC et al., 2016, Impaired dacarbazine activation and 7-ethoxyresorufin deethylation in vitro by polymorphic variants of CYP1A1 and CYP1A2: implications for cancer therapy., Pharmacogenet Genomics
    Lönn et al., 1987, Prevention of dacarbazine damage of human neoplastic cell DNA by aphidicolin., Cancer Res.
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Garbisa et al., 1997, Suppression of metastatic potential and up-regulation of gelatinases and uPA in LLC by protracted in vivo treatment with dacarbazine or razoxane., Int. J. Cancer
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Ma et al., Immunohistochemical analysis of DNA mismatch repair protein and O6-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy., Oncol. Rep.
    Singh et al., 1983, Comparison of the mutagenic responses of 12 anticancer drugs at the hypoxanthine-guanine phosphoribosyl transferase and adenosine kinase loci in Chinese hamster ovary cells., Environ Mutagen
    Shibuya et al., 2003, Induction of apoptosis and/or necrosis following exposure to antitumour agents in a melanoma cell line, probably through modulation of Bcl-2 family proteins., Melanoma Res.
    Altés A et al., 2013, Pharmacogenetic analysis in the treatment of Hodgkin lymphoma., Leuk Lymphoma
  • DACARBAZINE   POLA2

    Interaction Score: 23.78

    Interaction Types & Directionality:
    other/unknown

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    3098406 17016423 17139284


    Sources:
    TdgClinicalTrial TEND

  • DACARBAZINE   ADK

    Interaction Score: 1.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    6317371


    Sources:
    NCI

  • DACARBAZINE   MGMT

    Interaction Score: 0.5

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12168066


    Sources:
    NCI

  • DACARBAZINE   GSTM1

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23323945


    Sources:
    PharmGKB

  • DACARBAZINE   CYP1A1

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27428168


    Sources:
    PharmGKB

  • DACARBAZINE   PLAU

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9378540


    Sources:
    NCI

  • DACARBAZINE   BAX

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14512787


    Sources:
    NCI

  • DACARBAZINE   CXCL8

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DACARBAZINE   CYP1A2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27428168 22931300


    Sources:
    DTC PharmGKB

  • DACARBAZINE   CYP2C9

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • DACARBAZINE   CYP2C19

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • DACARBAZINE   CYP2D6

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • DACARBAZINE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TEND: DACARBAZINE

    • Version: 01-August-2011

    Alternate Names:
    DACARBAZINE Primary Drug Name

    Drug Info:
    Year of Approval 1975
    Drug Class antineoplastic agents

    Publications:

  • TdgClinicalTrial: DACARBAZINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antineoplastic Agents
    Drug Class small molecule
    FDA Approval 1975

    Publications:

  • NCI: DACARBAZINE

    • Version: 14-September-2017

    Alternate Names:
    C411 NCI drug code

    Drug Info:

    Publications:
    Singh et al., 1983, Comparison of the mutagenic responses of 12 anticancer drugs at the hypoxanthine-guanine phosphoribosyl transferase and adenosine kinase loci in Chinese hamster ovary cells., Environ Mutagen
    Shibuya et al., 2003, Induction of apoptosis and/or necrosis following exposure to antitumour agents in a melanoma cell line, probably through modulation of Bcl-2 family proteins., Melanoma Res.
    Garbisa et al., 1997, Suppression of metastatic potential and up-regulation of gelatinases and uPA in LLC by protracted in vivo treatment with dacarbazine or razoxane., Int. J. Cancer

  • DTC: DACARBAZINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL476 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • NCI: DTIC

    • Version: 14-September-2017

    Alternate Names:
    C411 NCI drug code

    Drug Info:

    Publications:
    Ma et al., Immunohistochemical analysis of DNA mismatch repair protein and O6-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy., Oncol. Rep.

  • PharmGKB: dacarbazine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Lewis BC et al., 2016, Impaired dacarbazine activation and 7-ethoxyresorufin deethylation in vitro by polymorphic variants of CYP1A1 and CYP1A2: implications for cancer therapy., Pharmacogenet Genomics
    Altés A et al., 2013, Pharmacogenetic analysis in the treatment of Hodgkin lymphoma., Leuk Lymphoma

  • TTD: Dacarbazine

    • Version: 2020.06.01

    Alternate Names:
    D0Y7ZU TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL476

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21